Compare UBFO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UBFO | SGMT |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.4M | 204.2M |
| IPO Year | N/A | 2023 |
| Metric | UBFO | SGMT |
|---|---|---|
| Price | $10.63 | $5.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 31.9K | ★ 527.1K |
| Earning Date | 01-22-2026 | 03-11-2026 |
| Dividend Yield | ★ 4.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $48,283,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.32 | $1.73 |
| 52 Week High | $11.05 | $11.41 |
| Indicator | UBFO | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 32.94 |
| Support Level | $10.35 | $5.88 |
| Resistance Level | $11.05 | $6.15 |
| Average True Range (ATR) | 0.26 | 0.36 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 62.50 | 21.98 |
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.